We were pleased to advise XRA 5 Corp on its acquisition of Mural Oncology plc. XRA is a wholly owned subsidiary of XOMA ...

The agreement values Mural Oncology at up to $36.2 million, with shareholders set to receive a base cash payment and ...

Clinical-stage California-based biotech Mural Oncology and XOMA Royalty Corporation , a biotechnology royalty aggregator have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly ...

A deal to acquire Alkermes spinout Mural Oncology is Xoma’s fourth since June and the latest evidence of interest in buying ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mural Oncology plc (NASDAQ: MURA) to XOMA Royalty Corporation for $2.035 per share and, up to an additional $0.205 ...

Mural Oncology plc (NASDAQ: MURA), a clinical-stage immuno-oncology company, and XOMA Royalty Corporation (NASDAQ: XOMA), a biotechnology royalty aggregator, announced today they have entered into a ...

Xoma Royalty is ravenous for biotechs, and the Bay Area licensing aggregator has found its next meal in Mural Oncology. | ...

Mural Oncology has agreed to be acquired by biotechnology royalty aggregator XOMA Royalty in a deal worth up to $38.8 million. Mural on Wednesday said XOMA will pay an initial $2.035 a share in cash, ...

Mural Oncology PLC (MURA) and XOMA Royalty Corporation (XOMA) announced on Wednesday that they have entered into a definitive ...

Xoma ( ($XOMA) ) has issued an update. On August 11, 2025, XOMA Royalty Corporation completed its merger with Turnstone Biologics Corp., following ...

Schrödinger announced it will discontinue clinical development of the CDC7 inhibitor SGR-2921 for acute myeloid leukemia (AML) and myelodysplastic syndromes following two patient deaths in an ...

Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, plus a contingent value right related to LAVA's two partnered assets and unp ...